It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Non-ischemic cardiomyopathy (NICM) can cause left ventricular dysfunction through interstitial fibrosis, which corresponds to the failure of cardiac tissue remodeling. Recent evidence implicates monocytes/macrophages in the etiopathology of cardiac fibrosis, but giving their heterogeneity and the antagonizing roles of macrophage subtypes in fibrosis, targeting these cells has been challenging. Here we focus on WWP2, an E3 ubiquitin ligase that acts as a positive genetic regulator of human and murine cardiac fibrosis, and show that myeloid specific deletion of WWP2 reduces cardiac fibrosis in hypertension-induced NICM. By using single cell RNA sequencing analysis of immune cells in the same model, we establish the functional heterogeneity of macrophages and define an early pro-fibrogenic phase of NICM that is driven by Ccl5-expressing Ly6chigh monocytes. Among cardiac macrophage subtypes, WWP2 dysfunction primarily affects Ly6chigh monocytes via modulating Ccl5, and consequentially macrophage infiltration and activation, which contributes to reduced myofibroblast trans-differentiation. WWP2 interacts with transcription factor IRF7, promoting its non-degradative mono-ubiquitination, nuclear translocation and transcriptional activity, leading to upregulation of Ccl5 at transcriptional level. We identify a pro-fibrogenic macrophage subtype in non-ischemic cardiomyopathy, and demonstrate that WWP2 is a key regulator of IRF7-mediated Ccl5/Ly6chigh monocyte axis in heart fibrosis.
Non-ischemic cardiomyopathy is a severe disease, characterized by interstitial fibrosis in the left ventricle of the heart. Here authors show that the E3 ubiquitin ligase WWP2 plays a pathogenic role in heart fibrosis via regulating a distinct monocyte population that initiates the process.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Duke-NUS Medical School, Programme in Cardiovascular and Metabolic Disorders, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); China Pharmaceutical University, Institute for Big Data and Artificial Intelligence in Medicine, School of Science, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793)
2 Duke-NUS Medical School, Programme in Cardiovascular and Metabolic Disorders, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924)
3 China Pharmaceutical University, Institute for Big Data and Artificial Intelligence in Medicine, School of Science, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793); Children’s Hospital of Nanjing Medical University, Department of Nephrology, Nanjing, China (GRID:grid.452511.6)
4 National Heart Centre Singapore, Singapore, Singapore (GRID:grid.419385.2) (ISNI:0000 0004 0620 9905)
5 Children’s Hospital of Nanjing Medical University, Department of Nephrology, Nanjing, China (GRID:grid.452511.6)
6 Duke-NUS Medical School, Programme in Cardiovascular and Metabolic Disorders, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); Imperial College London, Hammersmith Hospital, Centre for Inflammatory Disease, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923)